{
    "nct_id": "NCT03504241",
    "official_title": "Donor-derived Mesenchymal Stromal Cells, Alemtuzumab, Co-stimulation Blockade and Sirolimus for Tolerance Induction in Adult Kidney Allograft Recipients (ITN062ST)",
    "inclusion_criteria": "Recipient:\n\n* Adult candidates of an human leukocyte antigen (HLA)-non-identical, living-donor kidney transplant:\n\n  --Candidates must meet the United Network for Organ Sharing (UNOS) criteria, including laboratory criteria, for transplant listing;\n* Evidence of established immunity to Epstein-Barr Virus (EBV) as demonstrated by serologic testing;\n* Serological evidence of prior Cytomegalovirus (CMV) infection if donor is CMV positive;\n* For women of child bearing potential:\n\n  * A negative serum or urine pregnancy test with sensitivity of less than 50 mIU/mL within 72 hours of start of study medication; and\n  * Agreement to use contraception:\n\n    --- According to the FDA Office of Women's Health (http://www.fda.gov/birthcontrol), there are a number of birth control methods that are more than 80% effective\n\n    ----Female recipients of child-bearing potential must consult with their physician and determine the most suitable method(s) from this list to be used for 18 months after the first dose of study therapy.\n\nDonor:\n\n* Meets institutional selection criteria for organ and bone marrow donation:\n\n  --All donors will be screened and tested in accordance with:\n  * (i) FDA 21 CRF 1271.85 requirements for donors of human cells, tissues, and cellular- and tissue-based products (HCT/P); and\n  * (ii) standards for living kidney donors testing for infection established by the United Network for Organ Sharing (UNOS).\n* Ability to understand and provide informed consent for all study procedures including kidney transplant and bone marrow harvest.\nHealthy volunteers allowed\nMust have minimum age of 19 Years",
    "exclusion_criteria": "Recipient:\n\n* History of any immunodeficiency syndrome (including Human Immunodeficiency Virus-1 (HIV-1) and HIV-2);\n* Positive anti-Hepatitis C Virus (HCV) Polymerase Chain Reaction (PCR), anti-Hepatitis C Virus (HBV) PCR, or HBV surface antigen;\n* History of malignancy within 5 years of enrollment or any history of hematogenous malignancy or lymphoma; --Exception: Participants with curatively treated non-melanomatous skin cancer or curatively treated cervical carcinoma in situ may be enrolled.\n* Underlying renal disease with high likelihood of recurrence, including but not limited to:\n\n  * primary focal segmental glomerulosclerosis (FSGS),\n  * Type I or II membranoproliferative glomerulonephritis (MPGN),\n  * hemolytic-uremic syndrome and\n  * thrombotic thrombocytopenic purpura (HUS/TTP) syndrome. ---Subject(s) with end-stage renal disease (ESRD) of unknown etiology and/or has no histologically confirmed diagnosis, may be enrolled into the study as long as there are no clinical signs or symptoms consistent with excluded clinical diagnoses.\n* History of active M. tuberculosis:\n\n  --Participants with a history of latent M. tuberculosis (LTB) as defined by positive testing for tuberculosis using an approved IGRA blood test, such as QuantiFERON®-Gold TB or T-SPOT-TB assay must:\n  * have completed treatment for LTB and\n  * have a negative chest x-ray. ----All participants will undergo IGRA testing for M tuberculosis within 3 months prior to transplant.\n* Current or historical evidence of donor-specific antibody;\n* Immunosuppressive drug therapy within one year prior to enrollment.\n* May not be taking or have taken prednisone, cyclosporine A, tacrolimus, azathioprine, Mycophenolate Mofetil (MMF), cyclophosphamide, methotrexate, infliximab, etanercept, or other agents which have a primary therapeutic effect of immunosuppression in the year prior to transplantation.\n* May not have taken depletional anti-lymphocyte agents at any time.\n\n  ---Exceptions:\n  * Short (≤ 30 days) courses of topical or inhaled steroids are permitted, as are\n  * Short oral or parental pulses for a documented hypersensitivity reaction.\n* Active autoimmune disease requiring ongoing immunosuppressive therapy or other conditions in which there is an anticipated need for immunosuppressive maintenance therapy;\n* Uncompensated congestive heart failure, pulmonary edema, or symptomatic pulmonary hypertension;\n* Active severe infection within a month of the screening visit;\n* Use of an investigational drug within 30 days of the screening visit;\n* Presence of any medical condition that the investigator deems incompatible with trial participation; or\n* Inability or unwillingness to comply with protocol monitoring and therapy.\n\nDonor:\n\n* History of blood donation to the recipient;\n* Evidence of prior Cytomegalovirus (CMV) infection if the recipient is CMV negative;\n* History of HIV-1/HIV-2 infection;\n* Positive HCV PCR, HBV PCR or HBV surface antigen;or\n* Presence of any medical condition that the investigator deems incompatible with trial participation.",
    "miscellaneous_criteria": ""
}